Latest studies
- AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
This study is testing a new medicine, orelabrutinib, for people with a type of multiple sclerosis called Primary Progressive MS (PPMS). We want to see if it can slow down the worsening of symptoms compared to a dummy pill (placebo).
Primary Progressive Multiple Sclerosis (PPMS)Estonia - Active not recruitingPHASE3
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
This study is looking into a new way to treat lung damage (emphysema) caused by a rare condition called Alpha-1 Antitrypsin Deficiency (AATD). It compares two different doses of a medicine (Alpha-1 MP) to a dummy treatment over three years to see if it helps protect the lungs.
Pulmonary Emphysema in Alpha-1 PI DeficiencyEstonia - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
This study compares a new medicine, empasiprubart, with standard IVIg treatment for adults with CIDP. It looks at how well they work and if they are safe. Participants will receive one of these treatments, or a dummy treatment, for several months.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathyEstonia - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseEstonia - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsEstonia - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
This study is testing a new medicine called empasiprubart for adults with a nerve condition called CIDP. It wants to see if the medicine is safe and helps people feel better. Participants will get the study medicine or a dummy medicine first, then everyone will get the study medicine.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating PolyradiculoneuropathyEstonia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesEstonia - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
This study compares a new medicine, risankizumab, with a dummy treatment (placebo) for people with active psoriatic arthritis. It checks how safe and effective risankizumab is, especially for those who haven't responded well to other treatments.
Psoriatic ArthritisEstonia - Not yet recruiting
Validation of the European Oncology Quality of Life Toolkit
This study is testing a new set of online surveys called the EUonQoL-Kit. These surveys help understand the quality of life for people with cancer at different stages – during treatment, after treatment, and in palliative care. The goal is to make sure the surveys are accurate and helpful across Europe.
CancerSurvivorshipPalliative CareEstonia - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
Immunoglobulin A NephropathyEstonia - Active not recruitingPHASE3
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
This study looks at a medicine called tildrakizumab for psoriatic arthritis. It's for people who were already in earlier studies of this medicine. The aim is to see how safe and effective it is over a longer time, helping us understand its long-term benefits.
Psoriatic ArthritisEstonia - RecruitingPHASE3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This study is looking at a new medicine called darovasertib for people with a type of eye cancer called uveal melanoma. We want to see if taking darovasertib before standard treatments like radiation or surgery can help improve outcomes. It's a large study involving many hospitals.
Uveal MelanomaEstonia - Active not recruitingPHASE3
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
This study is looking at a new medication, filgotinib, for people with active axial spondyloarthritis (axSpA). We want to see if it helps reduce symptoms and is safe, comparing different doses to a dummy pill.
Axial SpondyloarthritisEstonia - Active not recruitingNA
COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
This study looks at a new way to treat blocked heart arteries. It compares two methods for deciding where to place stents: one using blood flow measurements, and another adding detailed artery scans. The aim is to see if combining these methods leads to better heart health.
Multivessel Coronary Artery DiseaseIschemiaVulnerable PlaqueCoronary Artery DiseaseEstonia - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study looks at new ways to treat ulcerative colitis, a condition causing gut inflammation. We're testing a combination of medicines (JNJ-78934804) for people whose current treatments aren't working well. The goal is to see if these new approaches are safe and effective.
Colitis, UlcerativeEstonia - Recruiting
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
This study looks at how well special rings and bands work to fix leaky heart valves (mitral and tricuspid regurgitation). It follows people who've had surgery with these Abbott devices for five years to make sure they're safe and effective.
Mitral RegurgitationTricuspid RegurgitationValvular Heart DiseaseEstonia - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisEstonia - Active not recruitingPHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
This study is testing a new medicine, inclisiran, to see if it can prevent serious heart problems like heart attacks and strokes in people who are at high risk but haven't had one before. They are comparing it to a dummy medicine.
Primary Prevention of Atherosclerotic Cardiovascular DiseaseEstonia - Recruiting
COVID-19 Vaccines Safety Tracking (CoVaST)
This study is looking at the side effects of COVID-19 vaccines in different groups of people, like healthcare workers and older adults. It aims to understand common side effects, who is more likely to get them, and any long-term effects. This helps build trust in vaccines.
Adverse Reaction to VaccineCOVID19 VaccineEstonia - RecruitingPHASE3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is testing a new drug, linvoseltamab, for people with a type of blood cancer called multiple myeloma. It compares this new drug to standard treatments to see how safe and effective it is, for patients who cannot have a stem cell transplant.
Multiple MyelomaEstonia - Active not recruitingNA
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
This study compares two ways to unblock heart arteries using stents for complex cases. It looks at whether using a special scanning tool, called OCT, during the procedure leads to better results over two years than standard methods.
Ischaemic Heart DiseaseIschemic Heart DiseaseEstonia - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
This study is testing a new medicine, risankizumab, for adults with active psoriatic arthritis, especially those who haven't responded well to other treatments. It aims to see how safe and effective it is in reducing symptoms.
Psoriatic Arthritis (PsA)Estonia - RecruitingPHASE3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
This study is for adults aged 18-75 recently diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML) or certain types of Myelodysplastic Syndrome. It tests a new drug, venetoclax, alongside standard chemotherapy, to see if this combination works better than chemotherapy alone.
Acute Myeloid LeukemiaEstonia - Enrolling by invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
This study looks at how well Esperoct® works and if it has side effects for men and boys with haemophilia A. Participants will receive their usual treatment and share information about their health over several years.
Haemophilia AEstonia - Active not recruitingPHASE3
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is testing a new vaccine (PCV21) for healthy babies aged 2 to 4 months. It aims to see if it's safe and helps babies make germ-fighting antibodies against pneumococcal disease, comparing it to an existing vaccine alongside their routine immunisations.
Pneumococcal ImmunizationHealthy VolunteersEstonia - Recruiting
European Disease Registry on Retinopathy of Prematurity (ROP)
This study is gathering information about premature babies across Europe who need treatment for a serious eye condition called Retinopathy of Prematurity (ROP). It helps doctors understand how the condition affects babies and what treatments are used.
Retinopathy of PrematurityEstonia - Active not recruitingPHASE3
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
This study looks at how safe and effective a new medicine, ESK-001, is for people with moderate to severe plaque psoriasis over a long time. It builds on previous studies and carefully watches patients who continue treatment.
Plaque PsoriasisPsoriasis (PsO)PsoriasisModerate PsoriasisEstonia - RecruitingPHASE2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called MORF-057 for adults with moderate to severe Crohn's disease. It compares different doses of the medicine to a dummy pill to see if it's safe and helps improve symptoms.
Inflammatory Bowel DiseasesCrohn's DiseaseEstonia - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This study looks at the long-term safety of a new medicine, itepekimab, for people with severe lung disease (COPD). It will also check if the medicine continues to help over time. Participants will have already been part of a previous study on this medicine.
Chronic Obstructive Pulmonary DiseaseEstonia - Active not recruitingPHASE3
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called guselkumab for people with psoriatic arthritis. It aims to see how well it reduces pain, swelling, and other symptoms compared to a dummy treatment, and if it helps improve their condition.
Arthritis, PsoriaticEstonia - Active not recruitingPHASE3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
This study is looking into new ways to treat advanced or recurrent womb cancer. We're testing a combination of medicines called durvalumab and olaparib, given after initial chemotherapy, to see if they can help patients live longer and better.
Endometrial NeoplasmsEstonia - RecruitingNA
LANDMARK Trial: a Randomised Controlled Trial of Myval THV
This study, called the LANDMARK Trial, is looking into how safe and effective a new heart valve called Myval THV is. It's compared to existing valves for people with a common heart condition called aortic valve stenosis. The goal is to see if it works just as well.
Aortic Valve StenosisEstonia - Enrolling by invitationPHASE3
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
This study is looking into the long-term safety of a treatment called Alpha-1 MP for people with a lung condition called Alpha-1 Antitrypsin Deficiency (AATD). It's for those who have already been part of a previous study and involves weekly drips of the medication.
Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyEstonia - Active not recruitingPHASE3
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at two new medicines, ofatumumab and siponimod, for children and teenagers aged 10-17 with multiple sclerosis (MS). It compares them to a medicine called fingolimod to see if they are safe and work well.
Multiple Sclerosis (MS)Estonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) – DHELIVER
This study, called DHELIVER, is testing a new treatment, HepaStem, for people with severe liver failure called ACLF. It aims to see if HepaStem can help people live longer and improve their liver health.
Estonia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia
This study is looking at a new antibiotic treatment called Zerbaxa for children with a specific type of lung infection they get while in hospital. It aims to see how safe it is, how well children tolerate it, and how the body handles the medicine.
Nosocomial infection, PneumoniaEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
Atopic DermatitisEstonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
This study is looking into a new medication called Tildacerfont for adults with a condition called classic congenital adrenal hyperplasia. It aims to see if Tildacerfont can help reduce the amount of steroid medicine (like hydrocortisone or prednisolone) people need to take.
Classic Congenital Adrenal HyperplasiaEstonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
This study is testing a new medicine, Tildacerfont, for adults with a condition called Classic Congenital Adrenal Hyperplasia (CAH). Doctors want to see if it helps reduce certain hormone levels and if it's safe to use.
Classic Congenital Adrenal HyperplasiaEstonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(waveLINE-004)
This study is testing a new medicine, Zilovertamab vedotin, for people with a type of blood cancer called Diffuse Large B-Cell Lymphoma. It's for patients whose cancer has come back or didn't respond to previous treatments. The main goal is to see how many people's cancer shrinks or disappears with this new drug.
Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies)Estonia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
This study looks at a new drug, Navtemadlin, for women with advanced endometrial cancer. It's for those who responded well to previous chemotherapy. The aim is to see if Navtemadlin can help keep the cancer from coming back for longer.
Advanced or Recurrent Endometrial CancerEstonia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder
This study is looking at a new medicine called Ulotaront for adults with generalised anxiety disorder. We want to see if it helps reduce anxiety and if it's safe to use. Some people will get the new medicine, and others will get a dummy pill.
generalised anxiety disorderEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, upadacitinib, for people aged 18 and over with moderate to severe eczema (atopic dermatitis). They want to see how well it clears up skin, reduces itching, and improves quality of life over 16 weeks compared to a dummy pill.
Moderate and Severe Atopic DermatitisEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
This study is testing a new medicine called Milvexian for people who have recently had a heart attack or similar heart problem. We want to see if it can prevent future serious heart issues better than existing treatments, with fewer side effects.
Acute Coronary SyndromeEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
This study looks at a new version of Eylea (a medicine for eye problems) to see if it's safe and works well for people with blurry vision caused by fluid build-up at the back of their eye. It compares the new version to the standard treatment.
Macular edema secondary to retinal vein occlusionEstonia - Ongoing, recruitingTherapeutic use (Phase IV)
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)
This study is looking at how a medicine called Cosentyx (secukinumab) might help adults with severe long-term sinus problems and nasal polyps, specifically when other treatments haven't worked well. It aims to see if Cosentyx can improve symptoms and reduce polyps.
Chronic rhinosinusitis with nasal polypsEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
This study is testing a new medication called asundexian against a standard treatment (apixaban) to see how well it prevents strokes or serious blood clots in people with atrial fibrillation, a type of irregular heartbeat. It's also looking at how safe the new drug is.
Prevention of stroke or systemic embolism in atrial fibrillationEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older.
This study looks at a new flu jab for people aged 50 and over. It compares how well this new high-dose jab works and its safety, against two other existing flu jabs. The aim is to find out if the new jab offers better protection.
Healthy individuals or individuals with stable comorbidities which increase their risk ofcomplications from influenza infection.Estonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis
This study compares a new medicine (BP16) with an existing one (Prolia®) for women with weak bones after menopause. Researchers will check if BP16 helps strengthen bones, how safe it is, and if the body reacts to it, over about a year and a half.
Post-Menopausal OsteoporosisEstonia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
This study compares two treatments for chronic lymphocytic leukaemia (CLL) in patients who haven't had treatment before and have other health issues. It's looking at how well a new combination of medicines works against a standard treatment, aiming to find safer and more effective options.
Chronic Lymphocytic Leukemia (CLL)Estonia